ijms-logo

Journal Browser

Journal Browser

TransportDEMENTIA5—From Advanced Technologies to Applied Translational Medicine

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 3273

Special Issue Editors


E-Mail Website
Guest Editor
MD, PhD, EFN, Department of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway
Interests: Alzheimer’s disease; ABC transporters; Huntington’s disease; neurodegeneration; neuropathology; neurology

E-Mail Website
Guest Editor
Medicinal Chemistry and Systems Polypharmacology, Medical Systems Biology Division, Lübeck Institute of Experimental Dermatology, University of Lübeck and University Medical Center Schleswig-Holstein, 23562 Lübeck, Germany
Interests: ABC transporters; Solute Carriers (SLCs); medicinal and pharmaceutical chemistry; molecular polypharmacology; structural biology; bioinformatics; drug development

Special Issue Information

Dear Colleagues,

It is our very pleasure to announce a Special Issue released by the International Journal of Molecular Sciences (IJMS) associated to the 5th meeting of our TransportDEMENTIA meeting series. The meeting will take place in the Capital of the Arctic, Tromsø, from August 28 until September 1, 2023. More information about the venue can be found on www.pahnkelab.eu/TD5.

The TransportDEMENTIA meeting series has established itself as a premier platform for cutting-edge research outlet amongst leading researchers from multiple disciplines. This year’s topic “From Advanced Technologies to Applied Translational Medicine” will strongly combine chemical biology, molecular mechanisms, and clinical implications of membrane-bound transporter systems in human health and disease, particularly:

• The Role of ABC and SLC Transporters in Health and Disease
   New Insights into the Pathophysiology of Transporter-related Processes
• The Role of ABC A1/A7 Transporters in Neurodegenerative Diseases
   From Risk Factors to Disease Rescue – Function of A-Group Transporters
• The Role of ABC and SLC Transporters in Drug Disposition and Discovery
   From Undesired Side Effects to Advanced Drug Development Pipelines
• Cellular and Animal Disease Models of Neurodegenerative Diseases
   New Disease Models – Links between Diseases and Translational Applications
• Transporter-associated Disease Model Systems
   In vitro, In vivo, and Clinical Applications
• Structural, Functional, and Regulatory Aspects of Transport Processes
   From Solute Translocation to Signal Transduction, Trafficking, and Cascades
• Improved Analytical Methods and New Assays
   New ABC Transporter Assays / Mass Spectrometry Imaging / OMICS
• New Advanced Technologies
   From Computational Interaction Prediction to AI and Imaging Techniques
• Multi-omics & Bioactivity Networks
   From Prote-, Metabol- and Lipidomics to Interactomics and Bioinformatics
• ABC Transporters for Clinical Use
   PET Imaging / Specific Metabolites for Disease Detection / Treatment
• Translation between Fields
   Methods / Assays / (Poly)pharmacology / Medicine / Animals / AI / Patients

TransportDEMENTIA5 prioritizes fruitful scientific discussions and exchange of information between scientists and clinicians of all career stages – particularly promoting our next-generation research force – connecting with global networks of excellent researchers. Together we will synergize to face and tackle the obstacles of today’s life sciences with a specific view on ABC and SLC transporters.

We welcome commentaries as well as original research and review articles related to the above topics. If you feel not represented but would like to contribute, please send us an enquiry.

The meeting attendees are particularly encouraged to submit their findings to this Special Issue, and a discount applies for every submission.

Prof. Dr. Jens Pahnke
Dr. Sven Marcel Stefan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2714 KiB  
Article
Apolar Extracts of St. John’s Wort Alleviate the Effects of β-Amyloid Toxicity in Early Alzheimer’s Disease
by Ahmed El Menuawy, Thomas Brüning, Iván Eiriz, Urs Hähnel, Frank Marthe, Luisa Möhle, Anna Maria Górska, Irene Santos-García, Helle Wangensteen, Jingyun Wu and Jens Pahnke
Int. J. Mol. Sci. 2024, 25(2), 1301; https://doi.org/10.3390/ijms25021301 - 21 Jan 2024
Cited by 1 | Viewed by 1642
Abstract
Hypericum perforatum (St. John’s wort) has been described to be beneficial for the treatment of Alzheimer’s disease (AD). Different extractions have demonstrated efficiency in mice and humans, esp. extracts with a low hypericin and hyperforin content to reduce side effects such as phototoxicity. [...] Read more.
Hypericum perforatum (St. John’s wort) has been described to be beneficial for the treatment of Alzheimer’s disease (AD). Different extractions have demonstrated efficiency in mice and humans, esp. extracts with a low hypericin and hyperforin content to reduce side effects such as phototoxicity. In order to systematically elucidate the therapeutic effects of H. perforatum extracts with different polarities, APP-transgenic mice were treated with a total ethanol extract (TE), a polar extract obtained from TE, and an apolar supercritical CO2 (scCO2) extract. The scCO2 extract was formulated with silicon dioxide (SiO2) for better oral application. APP-transgenic mice were treated with several extracts (total, polar, apolar) at different concentrations. We established an early treatment paradigm from the age of 40 days until the age of 80 days, starting before the onset of cerebral β-amyloid (Aβ) deposition at 45 days of age. Their effects on intracerebral soluble and insoluble Aβ were analyzed using biochemical analyses. Our study confirms that the scCO2H. perforatum formulation shows better biological activity against Aβ-related pathological effects than the TE or polar extracts. Clinically, the treatment resulted in a dose-dependent improvement in food intake with augmentation of the body weight, and, biochemically, it resulted in a significant reduction in both soluble and insoluble Aβ (−27% and −25%, respectively). We therefore recommend apolar H. perforatum extracts for the early oral treatment of patients with mild cognitive impairment or early AD. Full article
Show Figures

Figure 1

Review

Jump to: Research

16 pages, 652 KiB  
Review
Iron Overload in Brain: Transport Mismatches, Microbleeding Events, and How Nanochelating Therapies May Counteract Their Effects
by Eleonora Ficiarà, Ilaria Stura, Annamaria Vernone, Francesca Silvagno, Roberta Cavalli and Caterina Guiot
Int. J. Mol. Sci. 2024, 25(4), 2337; https://doi.org/10.3390/ijms25042337 - 16 Feb 2024
Cited by 1 | Viewed by 1003
Abstract
Iron overload in many brain regions is a common feature of aging and most neurodegenerative diseases. In this review, the causes, mechanisms, mathematical models, and possible therapies are summarized. Indeed, physiological and pathological conditions can be investigated using compartmental models mimicking iron trafficking [...] Read more.
Iron overload in many brain regions is a common feature of aging and most neurodegenerative diseases. In this review, the causes, mechanisms, mathematical models, and possible therapies are summarized. Indeed, physiological and pathological conditions can be investigated using compartmental models mimicking iron trafficking across the blood–brain barrier and the Cerebrospinal Fluid-Brain exchange membranes located in the choroid plexus. In silico models can investigate the alteration of iron homeostasis and simulate iron concentration in the brain environment, as well as the effects of intracerebral iron chelation, determining potential doses and timing to recover the physiological state. Novel formulations of non-toxic nanovectors with chelating capacity are already tested in organotypic brain models and could be available to move from in silico to in vivo experiments. Full article
Show Figures

Figure 1

Back to TopTop